Wird geladen...
Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
BACKGROUND: Abivertinib is a novel oral, third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that overcomes T790M‐induced resistance in non‐small cell lung cancer (NSCLC) patients. Here, we report the results of a complete and detailed clinical data of patients t...
Gespeichert in:
| Veröffentlicht in: | Thorac Cancer |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley & Sons Australia, Ltd
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7049520/ https://ncbi.nlm.nih.gov/pubmed/31943845 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13302 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|